In this issue:
- Enzalutamide in biochemically recurrent prostate cancer
- Enzalutamide + radium-223 in mCRPC
- Circulating lipid panel and clinical outcomes in mHSPC
- Statin use in apalutamide recipients with advanced prostate cancer
- Bevacizumab + erlotinib for hereditary and sporadic papillary kidney cancer
- Durvalumab + BCG for high-risk, NMIBC
- Erdafitinib in high- and intermediate-risk NMIBC
- Disitamab vedotin + toripalimab in HER2 expressing urothelial cancer
- Adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma
- Atezolizumab + BCG for NMIBC
- ctDNA-guided adjuvant atezolizumab for MIBC
Please login below to download this issue (PDF)